Am J Transplant, Volume 22, Suppl 3 Archives - Page 60 of 190 - ATC Abstracts

2022 American Transplant Congress
Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox
C. Debiais-Deschamps¹, O. Aubert¹, D. Yoo¹, G. Divard¹, C. Lefaucheur², C. Legendre³, A. Loupy¹
¹Université de Paris, PARCC, INSERM, Paris, France, ²Service de Transplantation Rénale, AP-HP, Hôpital Saint-Louis, Paris, France, ³Service de Transplantation Rénale Adulte, AP-HP, Hopital Necker, Paris, France
*Purpose: Predicting kidney transplant patient mortality has been hampered by registry-based studies and low level phenotyped cohorts without specific design towards mortality prediction. This represents…
2022 American Transplant Congress
Influence of the Competing Risk of Recipient Death on the Risk Estimation of Kidney Transplant Failure
M. Coemans¹, G. Verbeke², B. Döhler³, C. Süsal³, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²Leuven Biostatistics and Statistical Bioinformatics Centre, Leuven, Belgium, ³Heidelberg University Hospital, Heidelberg, Germany
*Purpose: Prognostic models for kidney transplant failure are often based on methods that censor for recipient death. Death is a competing event biasing the risk…
2022 American Transplant Congress
Vitrification of Pancreatic Islets and Transplantation
J. S. Rao¹, L. Zhan¹, D. Tobolt¹, M. Q. Slama², N. Sethia¹, Z. Han¹, C. S. Dutcher¹, Q. Peterson², J. C. Bischof¹, E. B. Finger¹
¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN
*Purpose: A limitation to potential cure for diabetes through islet transplantation is insufficient islet equivalence (IEQ) from a single donor to achieve insulin independence in…
2022 American Transplant Congress
Significant Reduction of Troponin I Elaboration After Ischemia Minimization in the First Hour of Ex Vivo Xeno Heart Perfusion
F. Pollok¹, M. R. Connolly¹, A. Calhoun¹, Z. Habibabady¹, S. Miura¹, M. Ma¹, S. Pratts¹, L. Burdorf¹, Y. Kan², J. V. Layer², J. V. Layer², E. Tan², R. Anand², M. Li², K. C. Hall², M. E. Youd², K. Stiede², W. Qin², M. Curtis², A. Azimzadeh¹, R. N. Pierson¹
¹Center for Transplantation Sciences, Massachusetts General Hospital, Cambridge, MA, ²eGenesis Inc., Cambridge, MA
*Purpose: Previous studies showed that ischemia minimization (IM), accomplished by perfusing the heart xenograft during storage, prevents ‘initial cardiac xenograft dysfunction’ (ICXD) and enables prolonged…
2022 American Transplant Congress
Consent to Organ Offers from Public Health Service Increased Risk Donors Decreases Time to Transplant and Waitlist Mortality
Y. Kelly, A. Zarinsefat, M. Tavakol, A. Shui, C. Huang, J. P. Roberts
University of California, San Francisco, San Francisco, CA
*Purpose: The Public Health Service Increased Risk designation identified organ donors at increased risk of transmitting hepatitis B, hepatitis C, and human immunodeficiency virus. Despite…
2022 American Transplant Congress
Can dd-cf DNA Eliminate Unnecessary Biopsies? The Answer is Yes!
K. Andreoni, Y. Chalicheemala, M. Debroy, M. Maklad, K. Zhao, M. Aeder, A. Jittirat, D. Ecabert, A. Bixby, C. Burrelli, K. Chavin
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Historically our center has been one that routinely performs biopsies. We perform them pre-perfusion, for slowly recovering allografts between day 10-14, and routinely at…
2022 American Transplant Congress
Perioperative Management of Live Donor Liver Transplantation: National Survey Results
C. Crouch¹, J. Ko², A. Hendrickse³, S. Kumar⁴, M. Little⁵, T. Sakai⁶
¹Department of Anesthesiology, University of Colorado, Aurora, CO, ²Department of Anesthesiology & Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, ³Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Department of Anesthesiology, UTHealth San Antonio, San Antonio, TX, ⁶Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Living donor liver transplantation (LDLT) is an emerging alternative for deceased donor liver transplantation (DDLT). In the United States (US), LDLT represented 5.3% (442/8345)…
2022 American Transplant Congress
Post-Operative Day 1 Galectin-3 is Predictive of Early Allograft Dysfunction in Liver Transplantation
D. Yoeli, T. Ferrell, I. Rodriguez, N. Limon De La Rosa, N. Nakra, Z. Wang, E. Cervantes-Alvarez, R. Choudhury, M. Adams, T. Nydam, E. Pomfret, C. Huang, N. Navarro Alvarez, H. Moore
University of Colorado Anschutz Medical, Aurora, CO
*Purpose: Early allograft dysfunction (EAD) is an important outcome measure in liver transplantation that is predictive of graft failure, but the mechanism behind it remains…
2022 American Transplant Congress
Pure Laparoscopic Donor Right Hepatectomy (PLDRH) – Can It be a Standardized, Reproducible and Cost Effective Procedure?
A. Kadimella, B. Palat, R. S
HPB and Liver Transplantation, AIG Hospitals, Hyderabad, India
*Purpose: Few centers in the world are doing PLDRH because of the long learning curve and donor safety concerns. Further longer operative time, difficulty in…
2022 American Transplant Congress
The Role of Gut Microbiota in Tacrolimus Blood Level Fluctuation, Time in Therapeutic Range and AlloSure Donor Derived Cell-Free DNA, Controlling for CYP3A5
M. Nayebpour¹, N. Koizumi¹, J. Melancon², M. Hasan²
¹George Mason University, Arlington, VA, ²George Washington University Hospital, Washington, DC
*Purpose: High tacrolimus variability (TV), low time in therapeutic range (TTR) and high percentage of donor derived cell-free DNA (dd-cfDNA) are associated with acute kidney…